Praxis Precision Medicines Inc

NASDAQ:PRAX   4:00:00 PM EDT
2.07
-0.07 (-3.27%)
6:28:12 PM EDT: $2.10 +0.03 (+1.45%)
Earnings Announcements

Praxis Precision Medicines Reports Third Quarter 2022 Financial Results

Published: 11/09/2022 21:11 GMT
Praxis Precision Medicines Inc (PRAX) - Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results.
Qtrly Loss per Share $0.96.
Prax-944 Phase 2b Essential1 Study Topline Results for Essential Tremor Expected in 1q23.
Prax-222 Embrave Study Forscn2a-dee to Initiate in 4q22; Topline Results for Initial Dose Cohort Expected in 2023.
Prax-628 Phase 1 Healthy Volunteer Study to Initiate in 4q22; Focal Epilepsy Study Planned for 2023.
Q3 Earnings per Share View $-0.89 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.73

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.69

More details on our Analysts Page.